- Home
- Publications
- Publication Search
- Publication Details
Title
The Treatment of Advanced Melanoma: Therapeutic Update
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 12, Pages 6388
Publisher
MDPI AG
Online
2022-06-10
DOI
10.3390/ijms23126388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM)
- (2022) Areeba Saif et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1–Resistant Melanoma
- (2022) Julia M. DeRogatis et al. Cancer Immunology Research
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Andrew Bottomley et al. LANCET ONCOLOGY
- Looking into a Better Future: Novel Therapies for Metastatic Melanoma
- (2021) Alessia Villani et al. Dermatology and Therapy
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
- (2021) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent Advances in the Treatment of Melanoma
- (2021) Brendan D. Curti et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
- (2021) Adi Diab et al. CLINICAL CANCER RESEARCH
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
- (2021) Chung-Hsing Chang et al. Tzu Chi Medical Journal
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
- (2020) Axel Hauschild et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
- (2020) Allison Betof Warner et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Advanced Melanoma in 2020 and Beyond
- (2020) Russell W. Jenkins et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
- (2020) Nikhil I Khushalani et al. Future Oncology
- Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
- (2020) Bonnie S. Glisson et al. CLINICAL CANCER RESEARCH
- Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits
- (2020) Alessia Villani et al. Expert Opinion On Drug Safety
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma
- (2019) Caroline Robert et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
- (2019) Johan Chanal et al. DERMATOLOGY
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Current state of melanoma diagnosis and treatment
- (2019) Lauren E. Davis et al. CANCER BIOLOGY & THERAPY
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
- (2019) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
- (2019) Juan Deng et al. OncoTargets and Therapy
- KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
- (2019) Jason J Luke et al. Future Oncology
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Cutaneous Melanoma—A Review in Detection, Staging, and Management
- (2018) Rebecca I. Hartman et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
- (2017) Georgina V Long et al. LANCET ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Overview of the Changing Landscape of Treatment for Advanced Melanoma
- (2017) Chung-Shien Lee et al. PHARMACOTHERAPY
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- (2016) Stephanie L. Goff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma
- (2015) Lynn E. Spitler et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
- (2015) Douglas B Johnson et al. Immunotherapy
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjusting for the Confounding Effects of Treatment Switching--The BREAK-3 Trial: Dabrafenib Versus Dacarbazine
- (2015) N. R. Latimer et al. ONCOLOGIST
- Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
- (2014) Pippa G Corrie et al. LANCET ONCOLOGY
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now